Intermittent parathyroid hormone administration stimulates bone formation in the mandibles of aged ovariectomized rats.
Intermittent administration of parathyroid hormone (PTH) is known to stimulate bone formation in many skeletal sites and is being investigated as a possible therapeutic agent for the treatment of osteopenic conditions, including post-menopausal osteoporosis. The purpose of this study was to determine the ability of PTH to stimulate bone formation in the mandibles of aged ovariectomized (Ovx) rats, and the results are compared with a site in the appendicular skeleton (humerus). The Ovx rat is a useful model of estrogen deficiency, replicating many aspects of post-menopausal osteoporosis. Female rats were ovariectomized or sham-operated, and one year later a group of the ovariectomized rats was treated with the 1-34 fragment of human PTH daily, five days a week for 10 weeks. During the experiment, the animals were given fluorochrome bone markers for histomorphometry. More than one year after ovariectomy or sham surgery, there were few differences in the histomorphometric indices of bone formation in the humerus or mandible. PTH treatment had no effect on dentin formation, measured in the mandibular incisor; however, most indices of bone formation-including the double-labeled surface, mineralizing surface, mineral appositional rate, new bone area, and surface-referent bone formation rates-were substantially greater in the PTH-treated group compared with both the Ovx and the Sham controls measured at the periosteal and endocortical surfaces of the humerus and the periosteal and cancellous bone surfaces of the mandible. In addition, bone formation at the alveolar crest, particularly on the buccal side, was greater in the PTH-treated group. The results from this study demonstrate that systemic intermittent PTH treatment stimulates bone formation in the mandibles in aged, estrogen-deficient animals.
Miller
S C
SC
Division of Radiobiology, School of Medicine, University of Utah, Salt Lake City 84112, USA.
Hunziker
J
J
Mecham
M
M
Wronski
T J
TJ
D000375:Aging; D000539:Alveolar Process / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D003804:Dentin / Q000502:physiology; D004195:Disease Models, Animal; D004967:Estrogens / Q000172:deficiency; D005260:Female; D006801:Humans; D006811:Humerus / Q000187:drug effects / Q000378:metabolism; D008334:Mandible / Q000187:drug effects* / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D010521:Periosteum / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D004967:Estrogens; D010281:Parathyroid Hormone